Crohn's Colitis Professional

Current Therapies and Those in the Pipeline Q & A

ReachMD Healthcare Image

This is a module of the session titled Current Therapies and Those in the Pipeline originally presented during the Crohn’s & Colitis Foundation Central Regional Professional Education Conference at Washington University: Cutting Edge Approaches to IBD Management on Sept 24, 2022, and supported in part by unrestricted educational grants from Boehringer Ingelheim, Bristol Myers Squibb, Ferring Pharmaceuticals, Janssen, and Pfizer, Inc.

  • Overview

    Please also watch the other modules from this session: IBD Immunology and Emerging Therapies, Small Molecules (JAKi/S1P agonists)IL-12/23 and IL-23 Receptor Antagonists, and the IBD Immunology and What is New in Anti -TNFs and Anti-Integrins?

  • Accreditation Information:

    You will receive credit for watching the other modules of this session but the Q & A portion is not accredited.

  • Learning Objectives

    The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:

    • Discuss studies to identify next generation IBD therapies
    • Analyze the literature of updates in use of anti-tnf and anti-integrin therapies in IBD
    • Describe the mechanism and rationale behind the development of targeted IL 12/23 and IL 23 inhibitors
    • Evaluate current efficacy and safety data for approved IL 23 inhibitors for the management of IBD and Crohn's disease
    • Identify the currently available janus kinase (JAK) inhibitors and S1P modulator for the treatment of moderate to severe ulcerative colitis
    • Implement the safety monitoring required prior to and during treatment with JAK inhibitors and S1P modulators

Facebook Comments


We’re glad to see you’re enjoying Crohn's Colitis Professional…
but how about a more personalized experience?

Register for free